Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) Director James Aloysius Brady Sells 824 Shares

Key Points

• Director James Aloysius Brady sold 824 shares of Verona Pharma PLC at $13.14 per share, bringing his total ownership down to 23,176 shares worth approximately $304,532.64.
• Verona Pharma's stock has seen a one-year range from a low of $19.45 to a high of $105.50, with a current price around $105.40 and a market capitalization of $8.97 billion.
• Recent ratings changes by several analysts have resulted in a consensus "Hold" rating for the stock, with a lowered average target price of $109.00.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA - Get Free Report) Director James Aloysius Brady sold 824 shares of the stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $13.14, for a total transaction of $10,827.36. Following the sale, the director directly owned 23,176 shares of the company's stock, valued at $304,532.64. This represents a 3.43% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Verona Pharma PLC American Depositary Share Stock Performance

Shares of VRNA stock traded down $0.07 during trading on Tuesday, reaching $105.40. 861,362 shares of the company's stock traded hands, compared to its average volume of 8,219,019. Verona Pharma PLC American Depositary Share has a 1 year low of $19.45 and a 1 year high of $105.50. The firm's 50-day moving average is $94.93 and its 200 day moving average is $74.38. The company has a current ratio of 8.86, a quick ratio of 8.73 and a debt-to-equity ratio of 1.07. The company has a market capitalization of $8.97 billion, a P/E ratio of -52.70 and a beta of 0.12.

Institutional Investors Weigh In On Verona Pharma PLC American Depositary Share

Institutional investors and hedge funds have recently modified their holdings of the company. NBC Securities Inc. bought a new stake in Verona Pharma PLC American Depositary Share during the first quarter worth about $34,000. IFP Advisors Inc purchased a new stake in shares of Verona Pharma PLC American Depositary Share during the second quarter worth about $52,000. Geneos Wealth Management Inc. increased its stake in shares of Verona Pharma PLC American Depositary Share by 44.2% during the first quarter. Geneos Wealth Management Inc. now owns 630 shares of the company's stock valued at $40,000 after buying an additional 193 shares during the period. Acadian Asset Management LLC purchased a new stake in shares of Verona Pharma PLC American Depositary Share in the 1st quarter worth about $48,000. Finally, NewEdge Advisors LLC purchased a new stake in shares of Verona Pharma PLC American Depositary Share during the first quarter valued at approximately $58,000. 85.88% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have weighed in on VRNA shares. BTIG Research downgraded shares of Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 10th. Roth Capital cut shares of Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 10th. Wells Fargo & Company downgraded Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating and lowered their price objective for the stock from $138.00 to $107.00 in a research note on Thursday, July 10th. Cowen cut Verona Pharma PLC American Depositary Share from a "buy" rating to a "hold" rating in a research report on Wednesday, July 9th. Finally, Piper Sandler downgraded Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 10th. Eleven equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $109.00.

Verona Pharma PLC American Depositary Share Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.